ViaOne™
The Heart’s Surface: Now Safely Within Reach
ViaOne™ is an FDA-cleared epicardial access device to create a stable, precise pathway to the heart’s surface – without an exposed needle to reduce the risk of heart perforation.
Why Change is Urgent
600K
sudden cardiac deaths annually in U.S. & Europe
10%
risk of severe complications with traditional access methods
$80k
average cost per
complication
35%
reduction in ventricular tachycardia (VT) when epicardial ablation is possible
Engineered for Surgical Confidence
SAFE
Blunt tip with concealed needle reduces puncture risk
PROTECTIVE
Proprietary gripping mechanism separates tissue without cutting
ACCURATE
Pressure sensor confirms precise pericardium placement
INTUITIVE
Easy-to-use design for fast adoption across experience levels
Watch How it Works
Blunt Tip, Concealed Needle
Reduces the risk of heart puncture
Proprietary Gripping Mechanism
Gently separates tissue without cutting
Pressure Sensor
Confirms precise position at the pericardium
Physician-Friendly
Safe and intuitive, even for less experienced users
Introducing ViaOne™:
Breakthrough Access to the Heart’s Surface
Protected. Precise. Confident.
ViaOne™ is the first FDA-cleared epicardial access device to create a stable, precise pathway to the heart’s surface – without an exposed needle – reducing the risk of heart perforation.
Unlocking a New World of Cardiac Therapies
ViaOne™ enables minimally invasive access to the heart’s surface – opening new treatment possibilities for a wide range of cardiac conditions, from rhythm disorders to regenerative care.
Arrhythmia Treatments
Mapping, ablation, & LAAC
Device Implantation
Epicardial leads & pacemakers
Advanced Therapies
Stem cell, gene, & targeted drug delivery
Structural & Ischemic Care
Myocardial infarction & HF interventions
Why Safer Heart Access Matters
From vessels, to valves, to the heart’s surface – the next leap is here.
The heart’s outer surface holds untapped life-saving potential for arrhythmia treatment, advanced therapies, and targeted drug delivery. Yet traditional access methods rely on sharp needles and uncontrolled force, putting patients at risk. That’s why ViaOne™ was built – to provide safe, reliable delivery for therapies patients need now, and those yet to come.
Conventional Entry –
Risk of Puncture
ViaOne™ Blunt Access –
Protects the Heart
From Breakthrough
to Real-World Impact
FDA Cleared
Breakthrough Device Designation (FDA)
Late-Breaking Clinical Trial
Clinically Validated
Clinical Publication in Top-Tier Medical Journal
Patented Technology
Strategic Partnership
News
Arrhythmia Treatments
Mapping, ablation, & LAAC
Device Implantation
Epicardial leads & pacemakers
Advanced Therapies
Stem cell, gene, & targeted drug delivery
Structural & Ischemic Care
Myocardial infarction & HF interventions
Meet Our Team
CardioVia is led by a team of innovators, clinicians, and medtech veterans, backed by global medical device leader, Terumo Corporation. Together, we are building the future of cardiac intervention.
Ziv Menshes
CEO & Co-founder (MBA, B.Sc.)
Experienced in medtech business strategy and operations, with a strong track record in bringing medical innovations to life.
Or Hazan
COO, Co-founder & Board Member (LLM, LLB)
Background in medical innovation and law; serving as Academic Officer at BioDesign Israel, The Hebrew University of Jerusalem.
Dr. Susan Alpert
Regulatory Affairs (PhD, MD)
Former SVP & Chief Regulatory Officer at Medtronic and Director for the Office of Device Evaluation at the U.S. FDA.
Kamal Abu Rizik
Product & Operations (B.Sc.)
12+ years in the medical device industry, specializing in innovative product design, scale-up, and compliance.
Ronny Barak
Senior Board Member, Strategic Business Development (MBA, B.Sc.)
25 years leading licensing, partnerships, and M&A in the life sciences sector.
Zohar Gendler
Chairman of the Board (M.Sc., B.Sc.)
Led investments in over 50 medtech companies, including Mazor Robotics (acquired by Medtronic) and Corindus (acquired by Siemens).
Scientific Advisory Board
Dr. Dhanunjaya R. Lakkireddy
Scientific Advisory Board Member (MD, FHRS)
Executive Director at Kansas City Heart Rhythm Institute with over 350 publications in cardiac electrophysiology.
Prof. David Luria
Medical Director (MD)
Director of the Arrhythmia Center and Head of Electrophysiology at Hadassah Medical Center.
THE FUTURE OF CARDIAC CARE
Safe, precise access to the heart’s surface, reducing rupture risk and transforming therapy potential.
ViaOne™ is a breakthrough, FDA-cleared platform designed for precise treatment delivery to the heart’s surface (pericardial space) — reducing the risk of heart puncture and unlocking a new generation of cardiac therapies.
The Heart’s Surface: Now Within Reach
ViaOne™ is a breakthrough, FDA-cleared platform designed for precise treatment delivery to the heart’s surface (pericardial space) — reducing the risk of heart puncture and unlocking a new generation of cardiac therapies.
FDA-Cleared stamp
Breakthrough Device Designation stamp
ViaOne™ is a breakthrough, FDA-cleared platform designed for precise treatment delivery to the heart’s surface (pericardial space) — reducing the risk of heart puncture and unlocking a new generation of cardiac therapies.
